fingolimod hydrochloride has been researched along with Recrudescence in 176 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (2.27) | 29.6817 |
| 2010's | 100 (56.82) | 24.3611 |
| 2020's | 72 (40.91) | 2.80 |
| Authors | Studies |
|---|---|
| Bian, ZX; Han, Q; Li, YH; Tang, HZ; Wang, L; Zhao, J; Zou, M | 1 |
| Bianco, A; Centonze, D; De Arcangelis, V; De Fino, C; De Luca, G; Di Lemme, S; Di Tommaso, V; Evangelista, L; Fantozzi, R; Lucchini, M; Mirabella, M; Pastorino, R; Presicce, G; Totaro, R | 1 |
| Abouelfath, A; Blin, P; Bosco-Lévy, P; Brochet, B; Debouverie, M; Diez, P; Droz-Perroteau, C; Guillemin, F; Heinzlef, O; Lassalle, R; Lignot, S; Louapre, C; Maillart, E | 1 |
| Alroughani, R; Barnett, M; Boz, C; Butler, E; Butzkueven, H; Buzzard, K; Duquette, P; Eichau, S; Girard, M; Grammond, P; Gresle, M; Hodgkinson, S; Jokubaitis, VG; Kalincik, T; Karabudak, R; Kermode, AG; Kuhle, J; Laureys, G; Lechner-Scott, J; Macdonell, R; McCombe, P; Monif, M; Prevost, J; Skibina, O; Slee, M; Stankovich, J; Taylor, B; van der Walt, A; Van Hijfte, L; van Pesch, V; Yeh, W; Zhong, M | 1 |
| Álvarez-Cermeño, JC; Fernández, O; Hernández, MA; Marzo, ME; Meca-Lallana, JE; Meca-Lallana, V; Montalbán, X; Muñoz, D; Olascoaga, J; Oreja-Guevara, C; Pato, A; Ramió-Torrentà, L; Rodríguez-Antigüedad, A | 1 |
| Acar-Ozen, P; Ayvacioglu Cagan, C; Bayraktar-Ekincioglu, A; Cakan, M; Goncuoglu, C; Karabudak, R; Karabulut, E; Tuncer, A | 1 |
| Ahle, G; Bigaut, K; Collongues, N; Courtois, S; de Seze, J; Fabacher, T; Fleury, M; Gaultier, C; Goudot, M; Kremer, L | 1 |
| Albrecht, H; Ettle, B; Haas, J; Klotz, L; Lang, M; Lang, S; Lassek, C; Schmidt, S; Schulze-Topphoff, U; Winkelmann, VE; Ziemssen, T | 1 |
| Hartung, HP; Korsen, M; Meuth, SG; Pfeuffer, S; Rolfes, L | 1 |
| Berger, E; Bourre, B; Cabre, P; Camdessanché, JP; Casey, R; Casez, O; Ciron, J; Clavelou, P; Couturier, J; De Sèze, J; Debouverie, M; Defer, G; Edan, G; Gout, O; Hankiewicz, K; Labauge, P; Laplaud, DA; Lebrun-Frenay, C; Leray, E; Maillart, E; Maurousset, A; Montcuquet, A; Moreau, T; Nasr, HB; Neau, JP; Pelletier, J; Pottier, C; Rollot, F; Ruet, A; Stankoff, B; Thouvenot, E; Vukusic, S; Wiertlewski, S; Zephir, H | 1 |
| Alroughani, R; Butzkueven, H; Buzzard, K; Eichau, S; Grammond, P; Havrdova, EK; Hodgkinson, S; Horakova, D; Izquierdo, G; Kalincik, T; Kappos, L; Lechner-Scott, J; Malpas, CB; Patti, F; Roos, I; Sharmin, S; Skibina, O | 1 |
| Počíková, Z; Štěpánová, R; Tichá, V; Vytlačil, J | 1 |
| Ács, P; Bencsik, K; Biernacki, T; Csányi, A; Cseh, B; Csépány, T; Dobos, E; Fricska-Nagy, Z; Füvesi, J; Horváth, L; Kincses, TZ; Kovács, K; Nagy, Z; Rózsa, C; Sandi, D; Vécsei, L | 1 |
| Celius, EG; Høgestøl, EA; Myhr, KM; Nygaard, GO; Skattebøl, L; Sowa, P; Torgauten, H; Torkildsen, Ø | 1 |
| Atula, S; Järvinen, E; Kuusisto, H; Rauma, I; Ryytty, M; Sipilä, JOT; Soilu-Hänninen, M; Viitala, M | 1 |
| Bove, RM; Gelfand, JM; Green, AJ; Guo, CY; Hsu, WY; Li, A; McPolin, K; Merrill, S; Rowles, WM | 1 |
| Acar Ozen, P; Anlar, B; Parlak, S; Solmaz, I; Tuncer, A | 1 |
| Butler, E; Butzkueven, H; Buzzard, K; Eichau, S; Girard, M; Hodgkinson, S; Jokubaitis, V; Kalincik, T; Lechner-Scott, J; Monif, M; Oh, J; Prevost, J; Skibina, O; van der Walt, A; Van Pesch, V; Zhong, M | 1 |
| Callens, A; Coustans, M; Edan, G; Jourdain, A; Lallement, F; Laplaud, D; Le Page, E; Leblanc, S; Leray, E; Michel, L; Videt, D; Wiertlewski, S | 1 |
| Croft, M; Gracias, D; Sethi, GS | 1 |
| Aguera-Morales, E; Al-Asmi, A; Alroughani, R; Amato, MP; Ampapa, R; Bakchine, S; Barnett, MH; Ben, NH; Berger, E; Bourre, B; Boz, C; Butler, EG; Butzkueven, H; Buzzard, K; Cabre, P; Cartechini, E; Casey, R; Castillo-Trivino, T; Ciron, J; Clavelou, P; Csepany, T; de Gans, K; De Seze, J; Debouverie, M; Edan, G; Eichau, S; Fragoso, YD; Gerlach, O; Girard, M; Gouider, R; Gout, O; Grammond, P; Grand'Maison, F; Havrdova, EK; Heinzlef, O; Hodgkinson, S; Horakova, D; Izquierdo, G; Kalincik, T; Kappos, L; Khoury, SJ; Labauge, P; Labeyrie, C; Laplaud, DA; Laureys, G; Lebrun-Frenay, C; Lechner-Scott, J; Leray, E; Macdonell, RA; Maillart, E; Malpas, C; Maubeuge, N; McCombe, PA; Moreau, T; Ozakbas, S; Patti, F; Pelletier, J; Prat, A; Prevost, J; Ramo-Tello, CM; Roos, I; Sánchez-Menoyo, JL; Shaygannejad, V; Sidhom, Y; Skibina, O; Slee, M; Sotoca, J; Soysal, A; Spitaleri, DLA; Stankoff, B; Terzi, M; Thouvenot, E; Turkoglu, R; Van der Walt, A; Van Hijfte, L; Van Pesch, V; Vucic, S; Vukusic, S; Wahab, A; Yamout, BI; Zephir, H | 1 |
| De Sèze, J; Edan, G; Kerbrat, A; Laplaud, DA; Le Page, E; Lebrun-Frenay, C; Lefort, M; Leguy, S; Leray, E; Lescot, L; Michel, L; Vukusic, S; Wiertlewski, S | 1 |
| Cano, S; Elliott, E; Jivraj, F; Kang, S; Kapadia, S; Reedie, S; Rock, M; Strzok, S | 1 |
| Bajeux, E; Chappuis, M; Edan, G; Kerbrat, A; Laplaud, D; Le Page, E; Michel, L; Rousseau, C; Wiertlewski, S | 1 |
| Aykaç, S; Eliaçık, S | 1 |
| Alroughani, R; Barnett, M; Boz, C; Butzkueven, H; Hodgkinson, S; Horakova, D; Izquierdo, G; Jokubaitis, V; Kalincik, T; Karabudak, R; Khoury, SJ; Kubala Havrdova, E; Kuhle, J; Lechner-Scott, J; Macdonell, R; Merlo, D; Monif, M; Onofrj, M; Ozakbas, S; Patti, F; Prat, A; Prevost, J; Roos, I; Skibina, O; Slee, M; van der Walt, A; Van Pesch, V; Zhou, Z; Zhu, C | 1 |
| Al-Asmi, A; Alroughani, R; Altintas, A; Ampapa, R; Blanco Morgado, Y; Butzkueven, H; Gerlach, O; Hodgkinson, S; Horakova, D; Kalincik, T; Kuhle, J; Laureys, G; Lechner-Scott, J; Macdonell, R; Oh, J; Ozakbas, S; Patti, F; Sanchez-Menoyo, JL; Soysal, A; Spelman, T; Spitaleri, D; Terzi, M; Tundia, N; Van Der Walt, A; van Pesch, V; Wong, SL; Yamout, B | 1 |
| Agan, K; Baba, C; Balcı, BP; Boz, C; Demirkıran, M; Efendi, H; Guler, S; Karabudak, R; Karahan, SZ; Kıylıoğlu, N; Köseoğlu, M; Ozakbas, S; Sevim, S; Soysal, A; Terzi, M; Tuncer, A; Turan, ÖF; Turkoglu, R; Yetkin, MF; Yüceyar, N | 1 |
| Fukumoto, S; Isobe, N; Masaki, K; Matsushita, T; Tanaka, E; Watanabe, M; Yamasaki, R | 1 |
| Alroughani, R; Boz, C; Butzkueven, H; Csepany, T; Grammond, P; Grand'Maison, F; Granella, F; Horakova, D; Kalincik, T; Lechner-Scott, J; Onofrj, M; Ozakbas, S; Patti, F; Prat, A; Spelman, T; Terzi, M; van der Walt, A; Zhu, C | 1 |
| Aguera-Morales, E; Al-Asmi, A; Al-Harbi, T; Alroughani, R; Altintas, A; Ampapa, R; Barnett, M; Bergamaschi, R; Blanco, Y; Boz, C; Butzkueven, H; Buzzard, K; Cartechini, E; Castillo-Triviño, T; Csepany, T; de Gans, K; Deri, N; Diouf, I; Duquette, P; Eichau, S; Ferraro, D; Fragoso, Y; Gerlach, O; Girard, M; Gouider, R; Grammond, P; Grand'Maison, F; Granella, F; Gray, O; Havrdova, EK; Hodgkinson, S; Horakova, D; Hughes, S; Izquierdo, G; Kalincik, T; Karabudak, R; Laureys, G; Lechner-Scott, J; Lugaresi, A; Maimone, D; Malpas, C; McCombe, P; McGuigan, C; Moore, F; Onofrj, M; Ozakbas, S; Patti, F; Petersen, T; Prat, A; Prevost, J; Ramo-Tello, C; Roos, I; Sa, MJ; Sanchez-Menoyo, JL; Schepel, J; Sempere, AP; Sharmin, S; Shaw, C; Shaygannejad, V; Skibina, O; Sola, P; Solaro, C; Soysal, A; Spitaleri, D; Terzi, M; Trevino-Frenk, I; Turkoglu, R; van der Walt, A; van Pesch, V; Van Wijmeersch, B; Yamou, B | 1 |
| Berger, É; Bigaut, K; de Sèze, J; Debouverie, M; Gauer, L; Moreau, T | 1 |
| Berger, T; Di Pauli, F; Enzinger, C; Guger, M; Kalcher, S; Kraus, J; Kvas, E; Leutmezer, F | 1 |
| Fakih, AU; Naser Moghadasi, A; Paybast, S; Sahraian, MA | 1 |
| Dardiotis, E; Doskas, T; Fakas, N; Grigoriadis, N; Iliopoulos, I; Karageorgiou, K; Maltezou, M; Mitsikostas, DD; Orologas, A; Vikelis, M | 1 |
| Akçalı, A; Akman, FG; Altunrende, B; Balcı, FB; Balgetir, F; Beckmann, Y; Birday, E; Boz, C; Cantürk, İA; Çelik, RGG; Demir, CF; Demirkıran, DM; Efendi, H; Ekmekçi, Ö; Eraksoy, M; Gazaloğlu, GB; Göncüoğlu, C; Işık, N; Kabay, SC; Kamişli, Ö; Karabudak, R; Kıylıoğlu, N; Kızılay, F; Köseoğlu, M; Kürtüncü, M; Mavi, K; Ölmez, Ç; Özcan, A; Özen, NPA; Saip, S; Sarıahmetoğlu, H; Sarıkaya, C; Sevim, MS; Siva, A; Soysal, A; Terzi, M; Toprak, MK; Tuncer, MA; Turan, ÖF; Türkoğlu, R; Uygunoğlu, U; Yüceyar, AN; Yüksel, S | 1 |
| Alkrenawi, M; Appel, S; Gelfand, A; Hovel, N; Menendez, L; Milo, R; Nitsan, Z; Osherov, M | 1 |
| Ciplea, AI; Gold, R; Hellwig, K; Hemat, S; Langer-Gould, AM; Thiel, S; Timmesfeld, N; Tokic, M | 1 |
| Alroughani, R; Barnett, M; Boz, C; Butler, E; Butzkueven, H; Buzzard, K; Duquette, P; Eichau, S; Garber, J; Gerlach, O; Girard, M; Grammond, P; Grand'Maison, F; Hodgkinson, S; Horakova, D; Izquierdo, G; Jokubaitis, V; Kalincik, T; Kermode, AG; Khoury, SJ; Kuhle, J; Laureys, G; Lechner-Scott, J; Macdonell, RAL; Merlo, D; Monif, M; Ozakbas, S; Patti, F; Prat, A; Prevost, J; Sa, MJ; Skibina, O; Slee, M; Terzi, M; van der Walt, A; Van Hijfte, L; Van Pesch, V; Van Wijmeersch, B; Weinstock-Guttman, B; Yamout, B; Zhou, Z; Zhu, C | 1 |
| Everest, E; Gorkey, OD; Gulec, B; Koc, M; Saip, S; Siva, A; Tutuncu, M; Uygunoglu, U | 1 |
| Brownlee, WJ; Duncan, J; Haghikia, A; Harty, GT; Hayward, B; Kayaniyil, S; Khan, Z; Millar, S; Waser, N | 1 |
| Aaen, G; Abrams, A; Benson, L; Casper, TC; Chitnis, T; Gorman, M; Goyal, M; Krupp, L; Liu, T; Lotze, T; Malani Shukla, N; Manlius, C; Mar, S; Ness, J; Rensel, M; Rodriguez, M; Rose, J; Schreiner, T; Tillema, JM; Waltz, M; Waubant, E; Weinstock-Guttmann, B; Wheeler, Y | 1 |
| Aguera-Morales, E; Al-Asmi, A; Al-Harbi, TM; Alroughani, R; Altintas, A; Ampapa, R; Bergamaschi, R; Boz, C; Butzkueven, H; Cartechini, E; Castillo-Trivino, T; Csepany, T; de Gans, K; Diouf, I; Duquette, P; Eichau, S; Ferraro, D; Gerlach, O; Gouider, R; Grammond, P; Grand'Maison, F; Granella, F; Gray, O; Hodgkinson, S; Horakova, D; Hughes, S; Iuliano, G; Kalincik, T; Kappos, L; Karabudak, R; Kubala Havrdova, E; Laureys, G; Lechner-Scott, J; Lugaresi, A; Malpas, CB; McCombe, PA; McGuigan, C; Onofrj, M; Ozakbas, S; Patti, F; Prat, A; Roos, I; Sa, MJ; Sánchez-Menoyo, JL; Sempere, AP; Sharmin, S; Shaw, C; Shaygannejad, V; Sidhom, Y; Slee, M; Sola, P; Solaro, C; Stuart, EA; Terzi, M; Treviño Frenk, I; van der Walt, A; Vucic, S; Yamout, B | 1 |
| Engin, E; Günal, D; Sünter, G; Vural, E; Yıldırım, KA | 1 |
| Ahle, G; Bigaut, K; Collongues, N; Courtois, S; de Seze, J; Dentel, C; Fickl, A; Fleury, M; Gaultier, C; Kolitsi, I; Kremer, L; Lanotte, L; Moreau, A; Mostoufizadeh, S; Sellal, F | 1 |
| Achiron, A; Angelucci, F; Halusková, S; Hartung, HP; Mareš, J; Pavelek, Z; Štourač, P; Tichá, V; Vališ, M | 1 |
| Bensimon, AG; Conway, D; Cox, GM; Herrera, V; Macheca, M; Peeples, M; Vieira, MC | 1 |
| Altobelli, C; Anastasio, P; Barbarulo, AM; Conchiglia, G; D'Amico, A; Di Pietro, A; Fratta, M; Lus, G; Rossi, F; Signoriello, E; Ugga, L | 1 |
| Abusamra, E; Ceccarelli, A; Hussain, SI; Mifsud, V | 1 |
| Andabaka, M; Basile, MS; Cavalli, E; Drulovic, J; Fagone, P; Ivanovic, J; Kalfin, R; Mammana, S; Martinovic, V; Mazzon, E; Mesaros, S; Nicoletti, F; Pekmezovic, T; Pennisi, M; Petralia, MC | 1 |
| Chen, CY; Cui, YM; Li, M; Ma, LY; Tian, X; Wu, Y; Yang, T; Zhou, S; Zhou, Y | 1 |
| Emming, S; Gobbi, C; Monticelli, S; Sacco, R; Zecca, C | 1 |
| Briner, M; Chan, A; Daponte, A; Diem, L; Evangelopoulos, ME; Findling, O; Gold, R; Hoepner, R; Kilidireas, C; Miclea, A; Salmen, A | 1 |
| Caire-Herrera, LE; Casallas-Vanegas, A; Coss-Rovirosa, F; Flores-Rivera, J; Gómez-Figueroa, E; Salado-Burbano, J | 1 |
| Bergmann, A; Braune, S; Heer, Y; Jules, E; Lionetto, F; Stühler, E; van Hövell, P; Westermann, C | 1 |
| Álvarez-Cermeño, JC; Ayuso, T; Contreras Martín, Y; Durán, C; Herrera Navarro, N; Martínez-Yelamos, S; Meca-Lallana, J; Meca-Lallana, V; Millán Pascual, J; Pérez Sempere, A; Ricart, J; Romero Sevilla, R | 1 |
| Boffa, G; Bruschi, N; Capello, E; Cellerino, M; Inglese, M; Lapucci, C; Novi, G; Sbragia, E; Uccelli, A | 1 |
| Albanese, M; Barbano, L; De Geronimo, D; Giorno, P; Landi, D; Marfia, GA; Parisi, V; Parravano, M; Ziccardi, L | 1 |
| Ara, JR; Barrero, F; Forero, L; Izquierdo, G; Mallada-Frechin, J; Martínez-Ginés, ML; Marzo, ME; Meca-Lallana, J; Meca-Lallana, V; Moreno, MJ; Oreja-Guevara, C; Sánchez-Vera, I | 1 |
| Aoki, R; Hirano, S; Kuwabara, S; Masuda, H; Mori, M; Ohtani, R; Uchida, T; Uzawa, A | 1 |
| Benkert, P; Décard, B; Derfuss, T; Hänni, P; Kappos, L; Kuhle, J; Lienert, C; Lorscheider, J; Moser, A; von Wyl, V; Yaldizli, Ö | 1 |
| Brinker, A; Croteau, D; Kortepeter, CM; Tobenkin, A | 1 |
| Carletti, S; Cerqua, R; Danni, M; Lattanzi, S; Rocchi, C; Silvestrini, M; Taffi, R | 1 |
| Alvarez, E; Corboy, JR; Nair, K; Sillau, S; Vollmer, BL; Vollmer, T | 1 |
| Ahmed, SF; Alroughani, R; Ibrahim Ismail, I; Salama, S | 1 |
| Bryll, A; Drabik, L; Karcz, P; Kolasinska, J; Kolasinska, M; Marona, M; Popiela, T; Skladzien, J; Slowik, A; Szaleniec, J; Wnuk, M; Ziekiewicz, M | 1 |
| Coutinho, AM; de Andrade, DC; de Lima, LGCA; de Souza Godoy, LF; Pimentel, GA | 1 |
| Azami, S; Konoeda, F; Sato, H | 1 |
| Doi, H; Fukai, R; Higashiyama, Y; Morihara, K; Nakamura, H; Takahashi, K; Takahashi, T; Takeuchi, H; Tanaka, F | 1 |
| Du Pasquier, R; Le Goff, G; Pantazou, V; Pot, C; Théaudin, M | 1 |
| Ataei, S; Ghiasian, M; Mohammadi, Y; Nafisi, H; Ranjbar, A | 1 |
| Englund, S; Fang, F; Frisell, T; Longinetti, E; Piehl, F; Reutfors, J | 1 |
| Brescia Morra, V; Capobianco, M; Cavalla, P; Cellerino, M; Ferraro, D; Guerra, T; Iaffaldano, P; Inglese, M; Lus, G; Malucchi, S; Mirabella, M; Paolicelli, D; Patti, F; Pisano, E; Sola, P; Trojano, M; Vitetta, F; Zaffaroni, M | 1 |
| Damas, F; Izquierdo, G; Navarro, G; Páramo, MD; Ruiz-Peña, JL | 1 |
| Forci, B; Mariottini, A; Massacesi, L; Mechi, C; Repice, A | 1 |
| Giovannoni, G; Hawkes, C; Lublin, F; Waubant, E | 1 |
| Achiron, A; Alroughani, R; Aref, H; Bijarnia, M; Cooke, K; Harb, M; Inshasi, J; Yuksel, O | 1 |
| Balk, LJ; Dekker, I; Killestein, J; Leurs, CE; Rispens, T; Uitdehaag, BM; van Kempen, ZL; Wattjes, MP | 1 |
| Barnett, M; Butler, E; Butzkueven, H; Duquette, P; Fabis-Pedrini, M; Ferraro, D; Girard, M; Grammond, P; Grand'Maison, F; Havrdova, E; Hodgkinson, S; Horakova, D; Hupperts, R; Jokubaitis, V; Kalincik, T; Kermode, A; Lechner-Scott, J; Lugaresi, A; McCombe, P; Prat, A; Prevost, J; Shaw, C; Slee, M; Sola, P; Solaro, C; Spelman, T; Terzi, M; Trojano, M | 1 |
| Havla, J; Hohlfeld, R; Kümpfel, T; Meinl, I | 1 |
| Brück, W; Ellenberger, D; Gärtner, J; Hummel, H; Huppke, B; Huppke, P; Rostasy, K; Stark, W | 1 |
| Berger, T; Enzinger, C; Guger, M; Kalcher, S; Kraus, J; Kvas, E; Leutmezer, F | 2 |
| Altintas, A; Saip, S; Siva, A; Tutuncu, M; Uygunoglu, U | 1 |
| Albrecht, H; Cornelissen, C; Haas, J; Klotz, L; Lang, M; Lassek, C; Medin, J; Schmidt, S; Tackenberg, B; Ziemssen, T | 1 |
| Buttari, F; Centonze, D; Di Iorio, G; Landi, D; Lus, G; Marfia, GA; Monteleone, F; Nicoletti, CG; Saccà, F; Sica, F; Signoriello, E | 1 |
| Banzi, R; Bertele', V; Garattini, S; Gerardi, C; Rossi, S | 1 |
| Bandini, F; Cavalla, P; Giordana, MT; Laroni, A; Mancardi, G; Uccelli, A; Vercellino, M | 1 |
| Annovazzi, P; Baroncini, D; Cocco, E; Cordioli, C; Fenu, G; Forci, B; Frau, J; Frigeni, B; Grasso, R; La Gioia, S; Lanzillo, R; Maniscalco, GT; Rasia, S; Realmuto, S; Rossi, S; Sartori, A; Signori, A; Signoriello, E; Sormani, MP; Stromillo, ML | 1 |
| Briner, M; Chan, A; Engelhardt, B; Evangelopoulos, ME; Hoepner, R; Huwiler, A; Miclea, A; Salmen, A; Schrewe, L | 1 |
| Mitsikostas, DD; Papadopoulos, D | 1 |
| Butzkueven, H; Hall, AJ; Lim, LL; Lo, TC; Pimentel, RS; Silva, DG | 1 |
| Friede, T; Häring, DA; Schmidli, H | 1 |
| Babb, J; Carraro, M; Hou, Q; Jhaveri, M; Livingston, T; Mendoza, JP; Nicholas, J; Ontaneda, D; Riester, K; Zhou, J | 1 |
| Duquette, P; Freedman, MS; Grand'Maison, F; Haddad, P; Khurana, V; Lara, N; Lee, L; Nakhaipour, HR; Schecter, R; Vorobeychik, G | 1 |
| Alroughani, R; Ampapa, R; Bergamaschi, R; Boz, C; Butler, E; Butzkueven, H; Duquette, P; Ferraro, D; Girard, M; Grammond, P; Grand'Maison, F; Granella, F; Hodgkinson, S; Horakova, D; Izquierdo, G; Jokubaitis, V; Kalincik, T; Kappos, L; Karabudak, R; Kubala Havrdova, E; Kuhle, J; Lechner-Scott, J; Lugaresi, A; McCombe, PA; Onofrj, M; Ozakbas, S; Pesch, VV; Prat, A; Prevost, J; Pucci, E; Ramo-Tello, C; Sánchez-Menoyo, JL; Shaygannejad, V; Slee, M; Sola, P; Solaro, C; Spelman, T; Spitaleri, D; Terzi, M; Trojano, M; Turkoglu, R; Van Wijmeersch, B; Vucic, S; Yamout, B | 1 |
| Bensimon, AG; Fox, E; Herrera, V; Johnson, K; Peeples, M; Signorovitch, J; Vieira, MC | 1 |
| Alonso-Magdalena, L; Dangond, F; Galazka, A; Martinelli, V; Pfleger, C; Phillips, L; Rieckmann, P; Vermersch, P | 1 |
| Alvarez, E; Corboy, JR; Nair, KV; Sillau, S; Vollmer, BL; Vollmer, T | 1 |
| Brownlee, WJ; Carroll, A; Chataway, J; John, N | 1 |
| Baroncini, D; Boffa, G; Callegari, I; Cellerino, M; Ghezzi, A; Inglese, M; Lapucci, C; Mancardi, GL; Novi, G; Pardini, M; Roccatagliata, L; Sormani, MP; Uccelli, A; Zaffaroni, M | 1 |
| Bhan, V; Fiander, MDJ; Parks, NE; Stewart, SA | 1 |
| Avendano, S; Cabre, P; de Roquemaurel, A; Galli, P; Landais, A | 1 |
| Hirano, S; Kojima, K; Kuwabara, S; Masuda, H; Mori, M; Ohtani, R; Uchida, T; Uzawa, A | 1 |
| Berenguer-Ruiz, L; Gimenez-Martinez, J; Palazón-Bru, A; Sempere, AP | 1 |
| Al Khedr, A; Barbin, L; Berger, E; Bourre, B; Brassat, D; Brochet, B; Cabre, P; Camdessanché, JP; Casey, R; Casez, O; Clavelou, P; De Sèze, J; Debouverie, M; Debroucker, T; Defer, G; Edan, G; Foucher, Y; Gout, O; Guennoc, AM; Heinzlef, O; Labauge, P; Labeyrie, C; Laplaud, DA; Lebrun-Frenay, C; Leray, E; Lubetzki, C; Magy, L; Maubeuge, N; Michel, L; Moreau, T; Nifle, C; Papeix, C; Patry, I; Pelletier, J; Rollot, F; Stankoff, B; Thouvenot, E; Tourbah, A; Vermersch, P; Vukusic, S; Wahab, A; Wiertlewski, S | 1 |
| Akatani, R; Chihara, N; Katanazaka, K; Matsumoto, R; Sekiguchi, K; Ueda, T | 1 |
| Bartosik-Psujek, H; Bielecki, B; Brola, W; Ciach, A; Czajka, A; Dorobek, M; Glabinski, A; Kapica-Topczewska, K; Kochanowski, J; Kulakowska, A; Kurkowska-Jastrzebska, I; Kurowska, K; Maciagowska-Terela, M; Nojszewska, M; Podlecka-Pietowska, A; Rusek, S; Siger, M; Stasiolek, M; Stepien, A; Tutaj, A; Walczak, A; Wicha, W; Wlodek, A; Zajdel, R; Zakrzewska-Pniewska, B | 1 |
| Barkhof, F; Cohen, JA; Comi, G; Eckert, B; Francis, G; Häring, DA; Izquierdo, G; Khatri, B; Montalban, X; Pelletier, J | 1 |
| Campbell, JD; Corboy, JR; McQueen, RB; Miravalle, A; Nair, K; Vollmer, TL | 1 |
| Airas, L; Malm, H; Ruuskanen, J | 1 |
| Bergmann, A; Braune, S; Lang, M | 1 |
| Agashivala, N; Balderston McGuiness, C; Bergvall, N; Capkun, G; Karkare, SU; Korn, JR; Lahoz, R; Makin, C; Petrilla, A; Pradhan, A | 1 |
| Ahmad, I; Deshmukh, VA; Gage, FH; Green, CC; Kerman, B; Kim, HJ; Kondo, T; Lairson, LL; Lawson, BR; Lyssiotis, CA; Padmanabhan, K; Schultz, PG; Swoboda, JG; Tardif, V; Theofilopoulos, AN | 1 |
| Agarwal, S; Deniz, B; Fox, RJ; Havrdova, E; Hutchinson, M; Kurukulasuriya, NC; Sarda, SP; Siddiqui, MK; Taneja, A | 1 |
| Agashivala, N; Bergvall, N; Capkun, G; Karkare, SU; Korn, JR; Lahoz, R; Makin, C; McGuiness, CB; Petrilla, AA; Pradhan, A | 1 |
| Bergvall, N; Korn, JR; Lahoz, R; Reynolds, T | 1 |
| Baldi, E; Caniatti, L; Curti, E; Ferraro, D; Granella, F; Guareschi, A; Immovilli, P; Montanari, E; Montepietra, S; Motti, L; Pesci, I; Senesi, C; Simone, AM; Sola, P; Tola, MR; Vitetta, F | 1 |
| Eienbröker, C; Gold, R; Havla, J; Hellwig, K; Hoepner, R; Hohlfeld, R; Kleiter, I; Kümpfel, T; Meinl, I; Tackenberg, B | 1 |
| Khatri, M; Rajasagi, NK; Reddy, PB; Rouse, BT; Sehrawat, S; Suryawanshi, A | 1 |
| Bertolotto, A; Capobianco, M; di Sapio, A; Malentacchi, M; Malucchi, S; Matta, M; Sperli, F | 1 |
| Barcella, V; Comi, G; Ferrè, L; Martinelli, V; Moiola, L; Radaelli, M; Sangalli, F | 1 |
| Almulla, A; Alroughani, R; Lamdhade, S; Thussu, A | 1 |
| Tang, Y | 1 |
| Batocchi, AP; Bianco, A; De Fino, C; Fetta, A; Frisullo, G; Marti, A; Mirabella, M; Nociti, V; Patanella, AK; Plantone, D; Rossini, PM | 1 |
| Bergvall, N; Cutter, G; Giovannoni, G; Nixon, R; Sfikas, N; Tomic, D | 1 |
| Chin, PS; Cutter, G; Hashmonay, R; Meng, X; Zahur Islam, M | 1 |
| Alroughani, R; Barnett, M; Bergamaschi, R; Boz, C; Butzkueven, H; Csepany, T; Duquette, P; Fernandez-Bolanos, R; Girard, M; Grammond, P; Grand'Maison, F; Havrdova, E; Hodgkinson, S; Horakova, D; Hupperts, R; Izquierdo, G; Jokubaitis, V; Kalincik, T; Lechner-Scott, J; Lugaresi, A; McCombe, P; Oreja-Guevara, C; Pucci, E; Rozsa, C; Rum, G; Sanchez-Menoyo, J; Simo, M; Slee, M; Spelman, T; Spitaleri, D; Terzi, M; Trojano, M; Verheul, F | 1 |
| Adinolfi, LE; Alfieri, G; Dalla Mora, L; Lus, G; Marrone, A; Rainone, I; Rinaldi, L; Signoriello, E | 1 |
| Francis, G; Hohlfeld, R; Kappos, L; O'Connor, P; Polman, C; Radue, EW; Ritter, S; Schlosshauer, R; Selmaj, K; von Rosenstiel, P; Zhang-Auberson, L | 1 |
| Barkley, A; Silber, E; Tully, T | 1 |
| Kawano, Y; Kira, J; Masaki, K; Matsuse, D; Matsushita, T; Murai, H; Sato, S; Song, ZY; Yamasaki, R; Yoshimura, S | 1 |
| Boangher, S; Goffette, S; Mespouille, P; Van Pesch, V | 1 |
| Chihara, N; Endo, H; Kanda, F; Kowa, H; Sekiguchi M D, K; Toda, T | 1 |
| Barkhof, F; Cohen, JA; Comi, G; Hartung, HP; Kappos, L; Khatri, B; Montalban, X; Pelletier, J; Ritter, S; Stites, T; Tomic, D; von Rosenstiel, P | 1 |
| Fernández Fournier, M; Gómez Fernández, C; González Ramos, J; Herranz Pinto, P; Mayor Ibarguren, A; Romero Gómez, MP; Tallón Barranco, A | 1 |
| Harel, A; Lublin, F; Straus Farber, R | 1 |
| Matsui, M | 1 |
| Andelova, M; Derfuss, T; Kappos, L; Lindberg, RL; Naegelin, Y; Rasenack, M; Rychen, J; Sprenger, T; Stippich, C | 1 |
| Maeda, Y; Miyazaki, T; Motomura, M; Nakajima, H; Shiraishi, H; Tanaka, K; Tsujino, A | 1 |
| Tanaka, M | 1 |
| Achtnichts, L; Benkert, P; Derfuss, T; Disanto, G; Du Pasquier, R; Findling, O; Gobbi, C; Kamm, CP; Kappos, L; Kuhle, J; Lalive, PH; Lorscheider, J; Lotter, C; Louvion, JF; Mattle, HP; Mueller, S; Nedeltchev, K; Pot, C; Radue, EW; Ramseier, S; Schluep, M; Sprenger, T; Stippich, C; Vehoff, J; Yaldizli, Ö; Zecca, C | 1 |
| Alping, P; Axelsson, M; Björck, A; Fink, K; Frisell, T; Islam-Jakobsson, P; Lycke, J; Malmeström, C; Novakova, L; Piehl, F; Salzer, J; Svenningsson, A | 1 |
| Koch-Henriksen, N; Magyari, M; Sellebjerg, F; Soelberg Sørensen, P | 1 |
| Crabtree-Hartman, E; Graves, JS; Hatcher, SE; Nourbakhsh, B; Waubant, E | 1 |
| Ayrignac, X; Cambron, M; Carra, C; Chouraki, A; Davion, JB; Duhin, E; Labauge, P; Lacour, A; Vermersch, P | 1 |
| Annovazzi, PO; Baroncini, D; Colombo, B; Comi, G; Ghezzi, A; Martinelli, V; Minonzio, G; Moiola, L; Rodegher, M; Zaffaroni, M | 1 |
| Mihalova, T; Salam, S; Siripurapu, R | 1 |
| Arcona, S; Li, Y; Taber, C; Zhou, H | 1 |
| Ando, K; Hashimoto, R; Kato, H; Ogawa, T; Otsuka, M; Tagawa, A; Tanabe, H; Tetsuka, S | 1 |
| Chan, A; Edwards, MR; Fox, RJ; Levison, D; Lewin, JB; Marantz, JL; Xiao, J; Zhang, A | 1 |
| Kadlecová, P; Kodým, R; Počíková, Z; Tichá, V | 1 |
| Lasek-Bal, A; Puz, P | 1 |
| Bianco, A; Brescia Morra, V; Buttari, F; Capra, R; Centonze, D; Cordioli, C; Cortese, A; Di Battista, G; Ferraro, E; Francia, A; Galgani, S; Gasperini, C; Haggiag, S; Millefiorini, E; Mirabella, M; Pontecorvo, S; Pozzilli, C; Prosperini, L; Ruggieri, S; Saccà, F | 1 |
| Dive-Pouletty, C; Freedman, MS; Hass, S; Leist, TP; Miller, AE; Montalban, X; Thangavelu, K | 1 |
| Afazel, S; de Vries, A; Harrer, A; Haschke-Becher, E; Hitzl, W; Kraus, J; McCoy, M; Oppermann, K; Pilz, G; Rispens, T; Sageder, M; Sellner, J; Stevanovic, V; Trinka, E; Wipfler, P | 1 |
| Tyor, WR; Vargas, DL | 1 |
| Bornstein, PF; Carpenter, AF; Goodwin, SJ; Larson, AJ; Markus, CK | 1 |
| Correale, J; Gaitán, MI | 1 |
| Candrian, U; Comi, G; Disanto, G; Ghezzi, A; Gobbi, C; Martinelli, V; Merlini, A; Messina, MJ; Moiola, L; Panicari, L; Patti, F; Perrone, P; Pravatà, E; Rodegher, M; Romeo, MAL; Stefanin, C; Zecca, C | 1 |
| Adlard, N; Allen, F; Bending, M; Firth, Z; Huisman, E; Jarrett, J; Papadimitropoulou, K | 1 |
| Asahara, T; Itamoto, T; Kobayashi, T; Kuroda, S; Miyata, Y; Ogawa, T; Ohdan, H; Tanimoto, Y; Tashiro, H; Ushitora, Y | 1 |
| Bonzano, L; De Stefano, N; Roccatagliata, L; Sormani, MP | 1 |
| Weinstock-Guttman, B; Yeh, EA | 1 |
| Arnason, B | 1 |
| Agarwal, S; Franklin, M; Meyer, K; Miller, RM; O'Day, K | 1 |
| Gerdes, LA; Havla, JB; Hohlfeld, R; Kümpfel, T; Meinl, I; Pellkofer, HL | 1 |
| Hao, Q; Itoyama, Y; Kikuchi, S; Kira, J; Kurosawa, T; Nagato, K; Saida, T; Tang, D; Zhang-Auberson, L | 1 |
| Albrecht, H; Berthele, A; Castrop, F; Haslinger, B; Hemmer, B; Kowarik, MC; Krause, M; Zimmer, C | 1 |
| Eckert, BJ; Roskell, NS; Rycroft, CE; Tyas, DA; Zimovetz, EA | 1 |
| Centonze, D; Gallo, P; Rinaldi, F; Rossi, S | 1 |
| Hartung, HP; Jander, S; Kieseier, BC; Turowski, B | 1 |
| Annovazzi, P; Baroncini, D; Comi, G; Filippi, M; Ghezzi, A; Minonzio, G; Rocca, MA; Zaffaroni, M | 1 |
| Hogan, WJ; Kuhr, CS; Lee, RS; Little, MT; Sale, GE; Storb, R; Zellmer, E | 1 |
| Baumann, DR; Cannet, C; Foster, CA; Hiestand, P; Rausch, M; Rudin, M | 1 |
| Bendszus, M; Stoll, G | 1 |
12 review(s) available for fingolimod hydrochloride and Recrudescence
| Article | Year |
|---|---|
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Neurodegenerative Diseases; Recurrence; Risk Assessment | 2023 |
The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta-analysis.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quality of Life; Recurrence | 2020 |
Preapproval and postapproval evidence on drugs for multiple sclerosis.
Topics: 4-Aminopyridine; Alemtuzumab; Clinical Trials as Topic; Crotonates; Daclizumab; Dimethyl Fumarate; Drug Development; European Union; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Natalizumab; Nitriles; Polyethylene Glycols; Recurrence; Toluidines; Treatment Outcome | 2018 |
[Multiple sclerosis and pregnancy].
Topics: Female; Fetus; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Maternal-Fetal Exchange; Multiple Sclerosis; Peptides; Pregnancy; Propylene Glycols; Recurrence; Sphingosine | 2013 |
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Topics: Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Disease Progression; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Randomized Controlled Trials as Topic; Recurrence; Sphingosine; Toluidines | 2014 |
Novel Agents for Relapsing Forms of Multiple Sclerosis.
Topics: Adjuvants, Immunologic; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Crotonates; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunoglobulin G; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Nitriles; Recurrence; Toluidines | 2016 |
Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
Topics: Administration, Oral; Adult; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome | 2017 |
Update on disease-modifying therapies for multiple sclerosis.
Topics: Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Daclizumab; Dimethyl Fumarate; Drug Approval; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunoglobulin G; Immunologic Factors; Infusions, Intravenous; JC Virus; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Polyomavirus Infections; Recurrence; Toluidines; Treatment Outcome; Tumor Virus Infections; United States; United States Food and Drug Administration | 2017 |
Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Topics: Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Severity of Illness Index | 2017 |
Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.
Topics: Administration, Oral; Brain; Cladribine; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Predictive Value of Tests; Propylene Glycols; Recurrence; Regression Analysis; Reproducibility of Results; Sphingosine; Time Factors; Treatment Outcome | 2011 |
Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
Topics: Activities of Daily Living; Administration, Oral; Bradycardia; Central Nervous System; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Female; Fingolimod Hydrochloride; Herpesviridae Infections; Humans; Immunosuppressive Agents; Macular Edema; Male; Multiple Sclerosis, Relapsing-Remitting; Neuroimmunomodulation; Neurologic Examination; Propylene Glycols; Receptors, Lysosphingolipid; Recurrence; Sphingosine; Treatment Outcome; Young Adult | 2011 |
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
Topics: Adult; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Peptides; Poisson Distribution; Propylene Glycols; Recurrence; Sphingosine; Time Factors | 2012 |
11 trial(s) available for fingolimod hydrochloride and Recrudescence
| Article | Year |
|---|---|
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
Topics: Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pregnancy; Recurrence | 2023 |
Antioxidative effects of silymarin on the reduction of liver complications of fingolimod in patients with relapsing-remitting multiple sclerosis: A clinical trial study.
Topics: Adult; Antioxidants; Chemical and Drug Induced Liver Injury; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Liver; Male; Middle Aged; Multiple Sclerosis; Recurrence; Silymarin | 2021 |
Uveitis in Patients with Multiple Sclerosis in Clinical Trials of Fingolimod: Incidence, Prevalence, and Impact on Disease Course.
Topics: Adult; Disease Progression; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Multiple Sclerosis; Prevalence; Recurrence; Treatment Outcome; Uveitis | 2019 |
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
Topics: Adult; Aging; Analysis of Variance; Brain; Data Interpretation, Statistical; Female; Fingolimod Hydrochloride; Humans; Image Processing, Computer-Assisted; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Recurrence; Sphingosine; Treatment Outcome | 2013 |
Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Double-Blind Method; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Injections, Intramuscular; Interferon beta-1a; Linear Models; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Time Factors; Treatment Outcome; Young Adult | 2015 |
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Topics: Adult; Antibodies, Monoclonal, Humanized; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Recurrence; Registries; Severity of Illness Index; Sphingosine; Treatment Outcome | 2015 |
Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
Topics: Adolescent; Adult; Brain; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Recurrence; Single-Blind Method; Sphingosine; Treatment Outcome; Young Adult | 2015 |
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.
Topics: Adult; Disability Evaluation; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Neuroimaging; Recurrence; Treatment Outcome; Young Adult | 2016 |
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Topics: Adult; Antibodies; Female; Fingolimod Hydrochloride; Humans; JC Virus; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Registries; Rituximab; Treatment Outcome; Young Adult | 2016 |
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Crotonates; Dimethyl Fumarate; Disability Evaluation; Disease Progression; Evidence-Based Medicine; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Numbers Needed To Treat; Recurrence; Severity of Illness Index; Toluidines; Treatment Outcome | 2016 |
A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis.
Topics: Adolescent; Adult; Asian People; Double-Blind Method; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Japan; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Odds Ratio; Propylene Glycols; Recurrence; Sphingosine; Time Factors; Treatment Outcome; Young Adult | 2012 |
153 other study(ies) available for fingolimod hydrochloride and Recrudescence
| Article | Year |
|---|---|
Anti-inflammatory Efficacy of Combined Natural Alkaloid Berberine and S1PR Modulator Fingolimod at Low Doses in Ulcerative Colitis Preclinical Models.
Topics: Animals; Anti-Inflammatory Agents; Berberine; Cell Line, Tumor; Colitis, Ulcerative; Cytokines; Dextran Sulfate; Drug Therapy, Combination; Fingolimod Hydrochloride; Male; Mice; Molecular Docking Simulation; Molecular Structure; Recurrence; Sphingosine-1-Phosphate Receptors; Spleen; STAT3 Transcription Factor | 2020 |
Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Recurrence; Retrospective Studies | 2021 |
Comparative effectiveness of dimethyl fumarate in multiple sclerosis.
Topics: Cohort Studies; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Treatment Outcome | 2022 |
Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2022 |
Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphopenia; Male; Middle Aged; Multiple Sclerosis; Recurrence; Registries; Retrospective Studies; Spain; Treatment Outcome | 2021 |
Factors associated with fingolimod rebound: A single center real-life experience.
Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies | 2021 |
Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2022 |
Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.
Topics: Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2022 |
Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2022 |
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal.
Topics: Antigens, CD20; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2022 |
Multiple Sclerosis Relapses Following Cessation of Fingolimod.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2022 |
Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months.
Topics: Czech Republic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Treatment Outcome | 2022 |
The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary.
Topics: Adult; Cross-Sectional Studies; Fingolimod Hydrochloride; Humans; Hungary; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2022 |
Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis.
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Rituximab | 2022 |
Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study.
Topics: Adult; Cladribine; Cohort Studies; Fingolimod Hydrochloride; Finland; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Registries; Tablets | 2022 |
Transitioning From S1P Receptor Modulators to B Cell-Depleting Therapies in Multiple Sclerosis: Clinical, Radiographic, and Laboratory Data.
Topics: Adult; Antigens, CD20; Female; Fingolimod Hydrochloride; Humans; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Sphingosine-1-Phosphate Receptors | 2022 |
Newer disease modifying treatments in pediatric onset multiple sclerosis: Experience from a single center.
Topics: Child; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies | 2022 |
Prediction of relapse activity when switching to cladribine for multiple sclerosis.
Topics: Chronic Disease; Cladribine; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2023 |
Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study.
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Recurrence; Retrospective Studies | 2022 |
Contribution of circulatory cells to asthma exacerbations and lung tissue-resident CD4 T cell memory.
Topics: Allergens; Animals; Asthma; CD4-Positive T-Lymphocytes; Fingolimod Hydrochloride; Immunologic Memory; Lung; Mice; Pneumonia; Recurrence | 2022 |
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies | 2022 |
Disease modifying therapies and disease activity during pregnancy and postpartum in a contemporary cohort of relapsing Multiple Sclerosis patients.
Topics: Female; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Postpartum Period; Pregnancy; Recurrence | 2022 |
The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study.
Topics: Cross-Sectional Studies; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Qualitative Research; Recurrence; Toluidines | 2022 |
Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies | 2023 |
What are the trends in the treatment of multiple sclerosis in recent studies? - A bibliometric analysis with global productivity during 1980-2021.
Topics: Alemtuzumab; COVID-19; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quality of Life; Recurrence | 2022 |
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
Topics: Cladribine; Cohort Studies; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Treatment Outcome; Withholding Treatment | 2022 |
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Topics: Cladribine; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Registries; Retrospective Studies; Tablets | 2023 |
The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Treatment Outcome | 2023 |
Effect of smoking on disease activity in multiple sclerosis patients treated with dimethyl fumarate or fingolimod.
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Smoking | 2023 |
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity.
Topics: Adult; Comparative Effectiveness Research; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Treatment Outcome | 2023 |
Comparative effectiveness in multiple sclerosis: A methodological comparison.
Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propensity Score; Recurrence; Treatment Outcome | 2023 |
A decade of fingolimod in multiple sclerosis: Insights from a large real-world cohort study.
Topics: Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2023 |
Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria.
Topics: Austria; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Treatment Outcome | 2023 |
Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies; Rituximab; Treatment Outcome | 2023 |
A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with Fingolimod.
Topics: Adult; Female; Fingolimod Hydrochloride; Greece; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Quality of Life; Recurrence; Treatment Outcome | 2023 |
Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE).
Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Recurrence; Retrospective Studies; Turkey | 2023 |
The consequences of switching from Gilenya® to generics for fingolimod.
Topics: Adult; Drugs, Generic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Treatment Outcome | 2023 |
Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Postpartum Period; Pregnancy; Recurrence; Registries | 2023 |
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neoplasm Recurrence, Local; Recurrence | 2023 |
Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five-year clinical outcomes.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2023 |
Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Tablets | 2023 |
Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments.
Topics: Adolescent; Adult; Child; Demography; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Recurrence | 2023 |
Real-life outcomes for oral disease-modifying treatments of relapsing-remitting multiple sclerosis patients: Adherence and adverse event profiles from Marmara University.
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Universities | 2023 |
Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study.
Topics: Adolescent; Child; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon beta-1a; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2023 |
Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study.
Topics: Adolescent; Adult; Crotonates; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Retrospective Studies; Time-to-Treatment; Toluidines; Treatment Failure; United States; Young Adult | 2020 |
Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis.
Topics: Adult; Alemtuzumab; Behavioral Symptoms; Brain Diseases; Brain Stem; Cognitive Dysfunction; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Mutism; Recurrence; White Matter; Young Adult | 2020 |
Short term real-world Fingolimod efficacy and safety in Emirati patients with multiple sclerosis.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Recurrence; Retrospective Studies; Treatment Outcome; United Arab Emirates | 2020 |
In Silico and In Vivo Analysis of IL37 in Multiple Sclerosis Reveals Its Probable Homeostatic Role on the Clinical Activity, Disability, and Treatment with Fingolimod.
Topics: Adult; Case-Control Studies; CD4-Positive T-Lymphocytes; Computer Simulation; Disease Progression; Diseases in Twins; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Humans; Interleukin-1; Male; Middle Aged; Multiple Sclerosis; Recurrence; Twins, Monozygotic; Up-Regulation | 2019 |
Rebound of disease activity after fingolimod withdrawal: Immunological and gene expression profiling.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Rituximab; T-Lymphocytes; Transcriptome | 2020 |
Dimethyl fumarate vs fingolimod following different pretreatments: A retrospective study.
Topics: Adult; Dimethyl Fumarate; Europe; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Recurrence; Retrospective Studies; Survival Analysis | 2020 |
Severe fingolimod rebound syndrome after switching to cladribine treatment.
Topics: Adult; Cladribine; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2020 |
Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis.
Topics: Algorithms; Bayes Theorem; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Models, Theoretical; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Precision Medicine; Prognosis; Recurrence; Treatment Adherence and Compliance | 2020 |
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies; Spain | 2020 |
Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
Topics: Adult; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Infections; Lymphocyte Count; Lymphocytes; Lymphopenia; Male; Multiple Sclerosis; Recurrence; Retrospective Studies; Risk | 2020 |
Choriocapillaris Integrity in Relapsed Central Serous Chorioretinopathy in a Patient Treated With Fingolimod for Multiple Sclerosis: New Insights From Optical Coherence Tomography Angiography.
Topics: Adult; Central Serous Chorioretinopathy; Choroid; Coloring Agents; Fingolimod Hydrochloride; Fluorescein Angiography; Humans; Immunosuppressive Agents; Indocyanine Green; Male; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tomography, Optical Coherence; Visual Acuity | 2021 |
Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.
Topics: Adult; Aged; Disabled Persons; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies; Spain | 2020 |
Comparison of brain atrophy in patients with multiple sclerosis treated with first- versus second-generation disease modifying therapy without clinical relapse.
Topics: Atrophy; Brain; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2020 |
Disability progression
Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2021 |
Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation.
Topics: Cognition; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2021 |
Long-term outcome in multiple sclerosis patients treated with fingolimod.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Longitudinal Studies; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Treatment Outcome | 2020 |
Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.
Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Outcome Assessment, Health Care; Recurrence; Retrospective Studies; Rituximab | 2020 |
Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Betacoronavirus; Child; Coronavirus Infections; COVID-19; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunologic Factors; Interferon-beta; Kuwait; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Recurrence; Rituximab; SARS-CoV-2; Surveys and Questionnaires; Telephone; Toluidines; Young Adult | 2020 |
Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying Therapies.
Topics: Anosmia; Dimethyl Fumarate; Fatigue; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2022 |
Intense Hypermetabolic Tumefactive Demyelination on 18F-FDG PET and MRI Related to Multiple Sclerosis Relapse After Fingolimod Suspension.
Topics: Biopsy; Female; Fingolimod Hydrochloride; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Middle Aged; Multimodal Imaging; Multiple Sclerosis; Myelin Sheath; Positron-Emission Tomography; Recurrence; Withholding Treatment | 2021 |
[A patient with relapsing-remitting multiple sclerosis who relapsed frequently and developed primary biliary cholangitis after pregnancy and discontinuation of fingolimod].
Topics: Adult; Autoantibodies; Biomarkers; Diagnosis, Differential; Female; Fingolimod Hydrochloride; Humans; Liver Cirrhosis, Biliary; Magnetic Resonance Imaging; Mitochondria; Multiple Sclerosis; Pregnancy; Pregnancy Complications; Recurrence; Withholding Treatment | 2021 |
Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment.
Topics: Adult; Aged; Autoantibodies; Biomarkers; Dimethyl Fumarate; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunity, Humoral; Immunosuppressive Agents; Male; Myelin-Oligodendrocyte Glycoprotein; Myelitis, Transverse; Optic Neuritis; Recurrence; Seroconversion; Steroids; Treatment Outcome | 2021 |
Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment.
Topics: Aged; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies | 2021 |
Risk of depression in multiple sclerosis across disease-modifying therapies.
Topics: Depression; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Recurrence | 2022 |
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.
Topics: Adult; Alemtuzumab; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2022 |
The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.
Topics: Adult; Disabled Persons; Female; Fingolimod Hydrochloride; Humans; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Safety | 2017 |
Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports.
Topics: Adult; Brain; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Recurrence | 2017 |
The 'Field Hypothesis': rebound activity after stopping disease-modifying therapies.
Topics: Animals; Fingolimod Hydrochloride; Humans; Immunologic Factors; Multiple Sclerosis; Recurrence | 2017 |
Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.
Topics: Adolescent; Adult; Aged; Cohort Studies; Disabled Persons; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Middle East; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Quality of Life; Recurrence; Young Adult | 2017 |
Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.
Topics: Adult; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Recurrence | 2018 |
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.
Topics: Adult; Cladribine; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propensity Score; Recurrence; Treatment Outcome | 2018 |
Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Pregnancy Complications; Recurrence | 2018 |
Therapy of highly active pediatric multiple sclerosis.
Topics: Adolescent; Child; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Natalizumab; Outcome Assessment, Health Care; Recurrence; Retrospective Studies; Severity of Illness Index | 2019 |
Real-life clinical use of natalizumab and fingolimod in Austria.
Topics: Adult; Austria; Cohort Studies; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propensity Score; Recurrence; Registries; Treatment Outcome; Young Adult | 2018 |
Factors Predictive of Severe Multiple Sclerosis Disease Reactivation After Fingolimod Cessation.
Topics: Adult; Brain; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Prognosis; Recurrence; Severity of Illness Index; Young Adult | 2018 |
Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA.
Topics: Adult; Demography; Female; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Observational Studies as Topic; Prospective Studies; Recurrence; Risk Assessment; Treatment Outcome | 2018 |
Fingolimod reduces the clinical expression of active demyelinating lesions in MS.
Topics: Adult; Brain; Contrast Media; Disability Evaluation; Drug Substitution; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunologic Factors; Interferon beta-1a; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Spinal Cord; Treatment Outcome | 2018 |
Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation.
Topics: Adult; Astrocytes; Autopsy; Brain; Fatal Outcome; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Receptors, Lysosphingolipid; Recurrence | 2018 |
Clinical activity after fingolimod cessation: disease reactivation or rebound?
Topics: Adolescent; Adult; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Italy; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Withholding Treatment; Young Adult | 2018 |
Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Recurrence; Retrospective Studies; Substance Withdrawal Syndrome | 2018 |
Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.
Topics: Adolescent; Adult; Aged; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Drug-Related Side Effects and Adverse Reactions; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Toluidines; Young Adult | 2018 |
Blinded continuous monitoring in clinical trials with recurrent event endpoints.
Topics: Age Factors; Biostatistics; Computer Simulation; Data Interpretation, Statistical; Endpoint Determination; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Models, Statistical; Monte Carlo Method; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic; Recurrence; Research Design; Sample Size; Time Factors; Treatment Outcome | 2019 |
Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Topics: Administration, Oral; Adolescent; Adult; Aged; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Secondary Prevention; Toluidines; Treatment Outcome; United States; Young Adult | 2019 |
The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis.
Topics: Adult; Female; Fingolimod Hydrochloride; Health Care Costs; Humans; Immunosuppressive Agents; Injections; Male; Middle Aged; Multiple Sclerosis; Recurrence; Retrospective Studies | 2019 |
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
Topics: Adult; Cohort Studies; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propensity Score; Proportional Hazards Models; Recurrence; Toluidines | 2019 |
Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3 years: a retrospective US claims database analysis.
Topics: Adult; Cohort Studies; Databases, Factual; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Insurance Claim Review; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Time Factors; United States | 2019 |
Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Topics: Alemtuzumab; Cladribine; Crotonates; Decision Support Techniques; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Recurrence; Risk Assessment; Toluidines | 2019 |
Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.
Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Recurrence; Treatment Outcome; Young Adult | 2019 |
Real-life use of oral disease-modifying treatments in Austria.
Topics: Administration, Oral; Adult; Austria; Cohort Studies; Crotonates; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propensity Score; Recurrence; Registries; Toluidines | 2019 |
Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis.
Topics: Adult; Alemtuzumab; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Integrin alpha4; Leukocyte Count; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neuromuscular Agents; Recurrence; Retrospective Studies | 2019 |
Different MRI patterns in MS worsening after stopping fingolimod.
Topics: Adult; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Recurrence; Retrospective Studies; Symptom Flare Up | 2019 |
Clinical Course of Relapsing Remitting Multiple Sclerosis Post-Natalizumab.
Topics: Adult; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies; Treatment Outcome | 2019 |
Fingolimod for the treatment of multiple sclerosis in French West Indies, a real-world study in patients from African ancestry.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Recurrence; Retrospective Studies; Treatment Outcome; West Indies | 2019 |
Relapse numbers and earlier intervention by disease modifying drugs are related with progression of less brain atrophy in patients with multiple sclerosis.
Topics: Adolescent; Adult; Aged; Atrophy; Brain; Disease Progression; Early Medical Intervention; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Young Adult | 2019 |
Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Glatiramer Acetate; Humans; Immunologic Factors; Interferon-beta; Multiple Sclerosis; Natalizumab; Pregnancy; Pregnancy Complications; Puerperal Disorders; Recurrence; Reproductive Behavior | 2019 |
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.
Topics: Adult; Crotonates; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Toluidines; Treatment Outcome | 2019 |
[Increased disease activity in a case of multiple sclerosis after switching treatment from fingolimod to natalizumab].
Topics: Adult; Antibodies; Disease Progression; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Injections, Intramuscular; Interferon-beta; Lymphocyte Count; Multiple Sclerosis; Natalizumab; Recurrence | 2019 |
Real-world effectiveness of fingolimod in Polish group of patients with relapsing-remitting multiple sclerosis.
Topics: Adult; Disabled Persons; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Poland; Recurrence | 2019 |
Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
Topics: Adult; Antibodies, Monoclonal, Humanized; Comparative Effectiveness Research; Cost-Benefit Analysis; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; JC Virus; Markov Chains; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Propylene Glycols; Quality-Adjusted Life Years; Recurrence; Sphingosine | 2013 |
Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort.
Topics: Adult; Antibodies, Monoclonal, Humanized; Cohort Studies; Disease Progression; Female; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Outpatients; Propylene Glycols; Recurrence; Sphingosine | 2013 |
Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
Topics: Adult; Databases, Factual; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; In Vitro Techniques; Insurance Claim Review; Interferons; Male; Middle Aged; Multiple Sclerosis; Peptides; Propylene Glycols; Recurrence; Retrospective Studies; Sphingosine; United States | 2013 |
A regenerative approach to the treatment of multiple sclerosis.
Topics: Animals; Antiparkinson Agents; Benztropine; Cell Differentiation; Coculture Techniques; Cuprizone; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immune System; Mice; Mice, Inbred C57BL; Models, Biological; Multiple Sclerosis; Myelin Proteolipid Protein; Myelin Sheath; Oligodendroglia; Optic Nerve; Propylene Glycols; Rats; Receptor, Muscarinic M1; Receptor, Muscarinic M3; Recurrence; Regeneration; Sphingosine; Stem Cells | 2013 |
Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.
Topics: Cohort Studies; Databases, Factual; Demography; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Insurance Claim Review; Interferons; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Peptides; Propylene Glycols; Recurrence; Sphingosine; Time Factors; United States | 2014 |
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal, Humanized; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Health Services; Hospitalization; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Propensity Score; Propylene Glycols; Recurrence; Retrospective Studies; Sphingosine; United States; Young Adult | 2014 |
Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
Topics: Adult; Antibodies, Monoclonal, Humanized; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Recurrence; Sphingosine; Treatment Outcome | 2014 |
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
Topics: Adult; Antibodies, Monoclonal, Humanized; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Recurrence; Retrospective Studies; Risk Factors; Sphingosine | 2014 |
An approach to control relapse of inflammatory lesions after discontinuation of primary therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Cell Differentiation; Disease Models, Animal; Female; Fingolimod Hydrochloride; Herpesvirus 1, Human; Immunosuppressive Agents; Interleukin-6; Keratitis, Herpetic; Mice; Mice, Knockout; Propylene Glycols; Receptors, Lysosphingolipid; Recurrence; Secondary Prevention; Sphingosine; T-Lymphocyte Subsets | 2014 |
No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.
Topics: Adult; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunologic Factors; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Outcome Assessment, Health Care; Recurrence; Retrospective Studies | 2015 |
Recurrence of disease activity after repeated Natalizumab withdrawals.
Topics: Adult; Disease-Free Survival; Female; Fingolimod Hydrochloride; Humans; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Treatment Outcome; Young Adult | 2015 |
Multiple sclerosis reactivation postfingolimod cessation: is it IRIS?
Topics: Adult; Antibodies, Monoclonal, Humanized; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Humans; Immune Reconstitution Inflammatory Syndrome; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Propylene Glycols; Recurrence; Sphingosine | 2014 |
Sample Size Estimation for Negative Binomial Regression Comparing Rates of Recurrent Events with Unequal Follow-Up Time.
Topics: Computer Simulation; Data Interpretation, Statistical; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Numerical Analysis, Computer-Assisted; Randomized Controlled Trials as Topic; Recurrence; Sample Size; Time Factors; Treatment Outcome | 2015 |
Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Cohort Studies; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Recurrence; Treatment Outcome | 2015 |
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Adult; Crotonates; Dimethyl Fumarate; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Models, Statistical; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Outcome Assessment, Health Care; Patient Acuity; Randomized Controlled Trials as Topic; Recurrence; Toluidines | 2014 |
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment.
Topics: Adult; Cholagogues and Choleretics; Epstein-Barr Virus Infections; Fingolimod Hydrochloride; Herpesvirus 4, Human; Humans; Immunocompromised Host; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Male; Multiple Sclerosis; Recurrence; Treatment Outcome; Ursodeoxycholic Acid; Withholding Treatment | 2014 |
Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod.
Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leg; Male; Multiple Sclerosis; Propylene Glycols; Recurrence; Remission, Spontaneous; Sarcoma, Kaposi; Sphingosine; Treatment Outcome | 2015 |
Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
Topics: Adult; Case-Control Studies; CD4-Positive T-Lymphocytes; Cytokines; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Recurrence; Treatment Outcome; Young Adult | 2014 |
Early relapse with tumefactive MS lesion upon initiation of fingolimod therapy.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Neurologic Examination; Recurrence; Young Adult | 2016 |
[A case of multiple sclerosis who relapsed early after fingolimod therapy introduced].
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Recurrence | 2015 |
Herpes zoster: a potential risk associated with fingolimod treatment.
Topics: Acyclovir; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Follow-Up Studies; Herpes Zoster; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Recurrence; Risk Assessment; Treatment Outcome; Valacyclovir; Valine | 2015 |
[How to use Japanese guidelines for the treatment of multiple sclerosis].
Topics: Acute Disease; Asian People; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Practice Guidelines as Topic; Recurrence | 2015 |
Efficacy and Safety of Fingolimod in an Unselected Patient Population.
Topics: Adult; Aged; Case-Control Studies; Cytokines; Dyspnea; Edema; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies | 2016 |
A case of recurrent optic neuritis associated with cerebral and spinal cord lesions and autoantibodies against myelin oligodendrocyte glycoprotein relapsed after fingolimod therapy.
Topics: Adolescent; Autoantibodies; Brain; Female; Fingolimod Hydrochloride; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Methylprednisolone; Myelin-Oligodendrocyte Glycoprotein; Myelitis; Optic Neuritis; Recurrence; Spinal Cord | 2016 |
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.
Topics: Adult; Aged; Female; Fingolimod Hydrochloride; Herpes Zoster; Humans; Immunocompromised Host; Immunosuppressive Agents; Incidence; Male; Middle Aged; Multiple Sclerosis; Recurrence; Secondary Prevention | 2016 |
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
Topics: Adult; Biomarkers; Brain; Cohort Studies; Demography; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Prognosis; Prospective Studies; Radiography; Recurrence; Switzerland | 2016 |
A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Prospective Studies; Recurrence; Treatment Outcome | 2017 |
Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Longitudinal Studies; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; PubMed; Recurrence | 2016 |
Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Recurrence; Substance Withdrawal Syndrome | 2016 |
Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Topics: Adolescent; Adult; Databases, Factual; Deprescriptions; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Interferons; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies; Treatment Failure; Treatment Outcome; Young Adult | 2016 |
Severe tumefactive rebound of multiple sclerosis following fingolimod cessation.
Topics: Adult; Brain; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Naltrexone; Narcotic Antagonists; Recurrence; Withholding Treatment | 2016 |
Difference-in-Differences Method in Comparative Effectiveness Research: Utility with Unbalanced Groups.
Topics: Adolescent; Adult; Chi-Square Distribution; Comparative Effectiveness Research; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Insurance Claim Review; Insurance, Health; Male; Middle Aged; Multiple Sclerosis; Probability; Recurrence; Regression Analysis; Retrospective Studies; United States; Young Adult | 2016 |
Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
Topics: Adult; Brain; Cervical Cord; Female; Fingolimod Hydrochloride; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2016 |
Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.
Topics: Adult; Czech Republic; Disability Evaluation; Disease Progression; Endpoint Determination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Treatment Outcome; Work | 2017 |
Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.
Topics: Adult; Disease Progression; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2016 |
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.
Topics: Adult; Disability Evaluation; Drug Resistance; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunologic Factors; Italy; Kaplan-Meier Estimate; Male; Multiple Sclerosis; Natalizumab; Propensity Score; Proportional Hazards Models; Recurrence; Retrospective Studies; Self Administration; Tertiary Care Centers; Treatment Outcome | 2017 |
From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.
Topics: Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Fingolimod Hydrochloride; Humans; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Radiography; Recurrence; Young Adult | 2017 |
Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
Topics: Adult; Cryptococcosis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Opportunistic Infections; Recurrence | 2017 |
Comment on extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
Topics: Chronic Disease; Fingolimod Hydrochloride; Humans; Leukoencephalopathy, Progressive Multifocal; Recurrence; White Matter | 2017 |
Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
Topics: Adult; Age Factors; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Count; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Recurrence; Retrospective Studies | 2018 |
Suppression of hepatocellular carcinoma recurrence after rat liver transplantation by FTY720, a sphingosine-1-phosphate analog.
Topics: Animals; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Cell Movement; Culture Media; Down-Regulation; Fingolimod Hydrochloride; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Propylene Glycols; Rats; Rats, Inbred BUF; Receptors, Lysosphingolipid; Recurrence; Sphingosine | 2009 |
MS Forum/MS Over the Past 17 Years.
Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Mitoxantrone; Multiple Sclerosis; Recurrence | 2011 |
Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
Topics: Antibodies, Monoclonal, Humanized; Cost-Benefit Analysis; Fingolimod Hydrochloride; Health Care Costs; Humans; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Propylene Glycols; Recurrence; Sphingosine; United States | 2011 |
Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
Topics: Brain; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Humans; Immunologic Factors; Interferon-beta; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Recurrence; Sphingosine; Treatment Outcome | 2012 |
Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?
Topics: Adult; Antibodies, Monoclonal, Humanized; Ataxia; Brain; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Plasma Exchange; Propylene Glycols; Recurrence; Sphingosine; Spine | 2012 |
Severe relapses under fingolimod treatment prescribed after natalizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Natalizumab; Propylene Glycols; Recurrence; Sphingosine | 2012 |
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.
Topics: Antibodies, Monoclonal, Humanized; Brain; Drug Administration Schedule; Drug Substitution; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Propylene Glycols; Recurrence; Sphingosine; Time Factors; Treatment Outcome | 2012 |
Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients.
Topics: Adult; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis; Propylene Glycols; Recurrence; Sphingosine; Substance Withdrawal Syndrome | 2013 |
FTY720 does not abrogate acute graft-versus-host disease in the dog leukocyte antigen-nonidentical unrelated canine model.
Topics: Acute Disease; Animals; Dogs; Fingolimod Hydrochloride; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Immunosuppressive Agents; Lymphocyte Count; Propylene Glycols; Recurrence; Severity of Illness Index; Sphingosine | 2003 |
Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging.
Topics: Acute Disease; Animals; Blood-Brain Barrier; Brain; Contrast Media; Dextrans; Encephalomyelitis, Autoimmune, Experimental; Female; Ferrosoferric Oxide; Fingolimod Hydrochloride; Heterocyclic Compounds; Immunohistochemistry; Immunosuppressive Agents; Iron; Macrophages; Magnetic Resonance Imaging; Magnetite Nanoparticles; Organometallic Compounds; Oxides; Propylene Glycols; Rats; Rats, Inbred Lew; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Recurrence; Sphingosine | 2004 |
Ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in experimental autoimmune encephalitis.
Topics: Animals; Blood-Brain Barrier; Brain; Contrast Media; Dextrans; Encephalomyelitis, Autoimmune, Experimental; Ferrosoferric Oxide; Fingolimod Hydrochloride; Heterocyclic Compounds; Immunohistochemistry; Immunosuppressive Agents; Iron; Macrophages; Magnetic Resonance Imaging; Magnetite Nanoparticles; Organometallic Compounds; Oxides; Propylene Glycols; Rats; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Recurrence; Sphingosine | 2005 |